American College of Clinical Pharmacy
      Search      Cart
         

Mon-94 - Impact of the Diabetes Health Equity Risk Score on Hemoglobin A1c in Value-Based Care Patients

Scientific Poster Session III: Resident and Fellows Research-in-Progress

Residents and Fellows Research in Progress
  Monday, November 13, 2023
  01:00 PM–02:30 PM

Abstract

Introduction: Health care models in the US are evolving to incorporate health equity considerations. Social determinants of health (SDOH) are indicators of health equity, which directly impact patient outcomes and may impact reimbursement in value-based care (VBC) health plans in the near future. The Diabetes Health Equity Risk Score (DM HERS) was developed to identify patients with type 2 diabetes (T2DM) with significant SDOH who would benefit from pharmacist intervention.

Research Question or Hypothesis: Does the use of the DM HERS improve outcomes in patients with VBC health plans?

Study Design: A single-center, retrospective, quasi-experimental study of patients with VBC health plans attributed to Atrium Health Wake Forest Baptist.

Methods: Adult patients with T2DM will be included. Patients will be excluded if they have a hemoglobin A1c (HbA1c) < 9%, lack repeat HbA1c post-intervention, were already receiving pharmacy chronic care management, or declined pharmacy services. The intervention will depend on DM HERS, with high-risk patients (score = 10) receiving chronic care management, and low-risk patient (score < 10) telephonic outreach from the Pharmacy Population Health Center (PPHC). The primary outcome is change in HbA1c pre- and post-intervention for the entire study population. Secondary outcomes include magnitude of change in HbA1c in the high-risk and low-risk groups, blood pressure control for patients with hypertension, weight management, and common pharmacist interventions.

The primary outcome will be evaluated using a t-test for difference in HbA1c pre- and post-intervention. The validity of DM HERS will be evaluated using a dichotomized analysis based on risk and response, allowing for the calculation of accuracy, sensitivity, and specificity of the risk assessment tool. Additional secondary outcomes will be analyzed with descriptive and inferential statistics.

Results: Results of this ongoing research project are still in process.

Conclusion: Conclusions of this ongoing research project are still in process.

Presenting Author

Ellen Montgomery PharmD
Atrium Health Wake Forest Baptist

Authors

Danielle Baker PharmD, MS, BCPS
Atrium Health Wake Forest Baptist

Christina Maki PharmD, BCPS
Atrium Health Wake Forest Baptist

Molly Hinely PharmD, BCPS
Atrium Health Wake Forest Baptist

Beth Williams PharmD
Atrium Health Wake Forest Baptist